Pharma

Pharma

Eli Lilly’s Jaypirca to dominate CLL BTK inhibitor market by 2032, says GlobalData

Despite the current Bruton tyrosine kinase (BTK) inhibitor market being valued at approximately $6 billion, sales specifically for chronic lymphocytic leukemia (CLL) are predicted to be nearly $5 billion by 2032 in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan). Eli Lilly’s Jaypirca (pirtobrutinib) is forecast to become the market leader […]

Pharma

Zosurabalpin may end 50-year antibiotic discovery stalemate against Acinetobacter baumanni, says GlobalData

Zosurabalpin, a novel antibiotic currently in Phase I development by Roche, has recently showed promise in ending a 50-year drought in effective treatment against carbapenem-resistant Acinetobacter Baumanni (CRAB), which is categorized by the World Health Organisation (WHO) as a “priority 1 pathogen.” Demonstrating efficacy in vitro and in mouse models, zosurabalpin targets a critical bacterial […]

Pharma

First-in-class Minerval shows promise in patients with advanced brain tumors, says GlobalData

Laminar Pharmaceuticals’ first-in-class autophagy inducer Minerval (LAM561, 2-hydroxyoleic acid (2-OHOA)) has reportedly demonstrated encouraging activity in the difficult-to-treat malignant braintumor patient population, placing it as a potential candidate for the treatment of glioma and other solid tumor malignancies. With a unique membrane-level targeting approach and encouraging early-stage clinical trial data, Minerval holds potential to address […]

Pharma

Female contraceptives market still requires therapeutics with better safety profiles, says GlobalData

The current unmet needs in the female contraceptives market are similar to those that were present 10 years ago. Currently, marketed contraceptives carry the risk of irregular bleeding patterns, weight gain, changes in mood, depression, migraine or headache, nausea, and acne. Side effects are one of the main reasons why patients may decide to discontinue […]

Pharma

Gout market across 7MM set to reach $10.8 billion in 2032 fueled by novel ULTs and rising prevalence, reveals GlobalData

The sales growth of gout therapies across the seven major markets (7MM: the US, 5EU, and Japan) is set to increase at a compound annual growth rate (CAGR) of 8.8% from $4.6 billion in 2022 to $10.8 billion in 2032, in line with the steadily increasing disease prevalence and the entrance of novel agents, according […]

Pharma

Amgen may potentially compete with established leaders in obesity, says GlobalData

On January 8, Amgen presented at JP Morgan’s 42nd Annual Healthcare Conference 2024 (JPM24), highlighting their pillars of business. One of these pillars was the general medicine franchise, which entailed the obesity space. The company has two promising pipeline agents in development for obesity that address the unmet needs of improved efficacy, faster weight loss, […]

Pharma

J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s growing investment trend, says GlobalData

Following the news that Johnson & Johnson (J&J) has entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Ambrx Biopharma for $2.0 billion; Israel Stern, MSc, Oncology & Hematology Analyst at GlobalData, a leading data and analytics company, offers his view: “J&J will have the rights to antibody-drug conjugate (ADC)-focused biotech, which includes anvatabart […]

Pharma

AbbVie’s Produodopa holds potential to become first-choice pump for advanced Parkinson’s, says GlobalData

Following the news that AbbVie has launched Produodopa (foscarbidopa/foslevodopa), to treat severe motor fluctuations in patients with advanced Parkinson’s disease (PD) in the European Union (EU). Christie Wong, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “AbbVie’s Produodopa is the first-to-market subcutaneous infusion of levodopa. Produodopa uses a VYAFUSER pump […]

Pharma

Biotech funding recovery is on the horizon in 2024, says GlobalData

Over 2022 and 2023, biotech funding saw significant change, with a marked downturn in investment. Hoverer, the post-pandemic slump is expected to end with the market heading to recovery in 2024, finds GlobalData, a leading data and analytics company. A recent GlobalData’s survey “The State of the Biopharmaceutical Industry 2024” found that overall, more than […]

Pharma

Bluebird second reimbursement deal provides valuable advantage for Lyfgenia in upcoming battle for market share, says GlobalData

Following the news that Massachusetts-based biotechnology company bluebird bio Inc (bluebird bio) has signed a second outcomes-based reimbursement deal with a large commercial payer for its sickle cell disease gene therapy, Lyfgenia (lovotibeglogene autotemcel); Nancy Jaser, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Combined with its first coverage […]

Pharma

MDD market across 8MM to reach $9.6bn by 2029 driven by novel drug launches, says GlobalData

The major depressive disorder (MDD) market is forecast to grow from $4.7 billion in 2019 to $9.6 billion by 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 7.4%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Major Depressive Disorder: Eight-Market Drug Forecast and Market […]

Pharma

Age-related macular degeneration market across 7MM set to reach $27.5 billion in 2031, forecasts GlobalData

The age-related macular degeneration market (AMD) in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is set to grow from $7.4 billion in 2021 to $27.5 billion in 2031, driven by the launch of longer-acting anti-vascular endothelial growth factor (VEGF) therapies to treat patients with AMD, an increase […]

Pharma

Addressing unmet needs of bronchiectasis key to develop effective treatments, says GlobalData

Although not a common disease, bronchiectasis has been in the spotlight of research as no therapies have been approved for its treatment. Bronchiectasis is a disease characterised by the abnormal enlargement of the bronchi in the lungs and the overproduction of mucus, which results in a poor quality of life, with physicians urging for improved […]

Pharma

India’s fight against rare diseases needs more focus on awareness and diagnosis, says GlobalData

In November 2023, the Indian Union Health Ministry authorised the sale of four generic medications for the treatment of rare diseases. This approval is a significant milestone in the fight against rare diseases in India. These approved indigenous products, along with other products yet to be approved, will aid patients suffering from rare diseases. However, […]

Pharma

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent survey launched by GlobalData, a leading data and analytics company. The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of […]

Pharma

Casgevy approval unlikely to be followed up by another CRISPR drug in near future, says GlobalData

Vertex Pharmaceuticals and CRISPR Therapeutics made history last month by gaining approval for the first CRISPR-based drug, exagamglogene autotemcel (Casgevy). However, given that 88% of CRISPR drugs are in the early stages of development, it is unlikely to see another CRISPR approval any time soon, says GlobalData, a leading data and analytics company. In November […]

Pharma

Gaucher disease market to reach $1.3 billion across 7MM in 2032, forecasts GlobalData

The market for Gaucher disease, a rare inherited metabolic disorder characterized by hepatosplenomegaly, bone disease, and anemia, is set to experience a compound annual growth rate (CAGR) of 0.79% across the seven major markets (7MM*) from $1.2 billion in 2022 to $1.3 billion in 2032, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest […]

Pharma

Ractigen’s RAG-01 becomes second saRNA drug globally to advance to clinical stage, says GlobalData

Ractigen Therapeutics, headquartered in China, submitted a clinical trial application for RAG-01 in Australia. This application paves the way for Phase I trial of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC) who have not responded to Bacillus Calmette-Guérin (BCG) therapy, making it globally the second saRNA drug to advance into the clinical stage, says […]

Pharma

Dual orexin receptor antagonists to drive insomnia market across 7MM to $4.1 billion in 2032, says GlobalData

The insomnia market across the seven major markets (7MM*) is poised to grow at a compound annual growth rate (CAGR) of 2.6% from $3.2 billion in 2022 to $4.1 billion in 2032, driven by an increase in the patient share of dual orexin receptor antagonists (DORAs) and the anticipated introduction of four late-stage pipeline products, […]

Pharma

Geopolitical conflicts, inflation, and drug pricing pressures will be top challenges for pharma industry growth in 2024, finds GlobalData

Lingering inflation, geopolitical tensions, and conflicts, as well as continuous pressures to cut drug prices, will be the top challenges for the pharmaceutical industry in 2024, finds GlobalData, a leading data and analytics company. GlobalData’s recent survey “The State of the Biopharmaceutical Industry 2024” found that drug pricing and reimbursement constraints elicited the strongest responses […]

Prev 1 … 24 25 26 27 28 … 108 Next

Eli Lilly’s Jaypirca to dominate CLL BTK inhibitor market by 2032, says GlobalData

Zosurabalpin may end 50-year antibiotic discovery stalemate against Acinetobacter baumanni, says GlobalData

First-in-class Minerval shows promise in patients with advanced brain tumors, says GlobalData

Female contraceptives market still requires therapeutics with better safety profiles, says GlobalData

Gout market across 7MM set to reach $10.8 billion in 2032 fueled by novel ULTs and rising prevalence, reveals GlobalData

Amgen may potentially compete with established leaders in obesity, says GlobalData

J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s growing investment trend, says GlobalData

AbbVie’s Produodopa holds potential to become first-choice pump for advanced Parkinson’s, says GlobalData

Biotech funding recovery is on the horizon in 2024, says GlobalData

Bluebird second reimbursement deal provides valuable advantage for Lyfgenia in upcoming battle for market share, says GlobalData

MDD market across 8MM to reach $9.6bn by 2029 driven by novel drug launches, says GlobalData

Age-related macular degeneration market across 7MM set to reach $27.5 billion in 2031, forecasts GlobalData

Addressing unmet needs of bronchiectasis key to develop effective treatments, says GlobalData

India’s fight against rare diseases needs more focus on awareness and diagnosis, says GlobalData

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

Casgevy approval unlikely to be followed up by another CRISPR drug in near future, says GlobalData

Gaucher disease market to reach $1.3 billion across 7MM in 2032, forecasts GlobalData

Ractigen’s RAG-01 becomes second saRNA drug globally to advance to clinical stage, says GlobalData

Dual orexin receptor antagonists to drive insomnia market across 7MM to $4.1 billion in 2032, says GlobalData

Geopolitical conflicts, inflation, and drug pricing pressures will be top challenges for pharma industry growth in 2024, finds GlobalData

Browse

Company information